Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Biochim Biophys Acta. 2011 Oct 20;1822(2):139–149. doi: 10.1016/j.bbadis.2011.10.010

Figure 1.

Figure 1

EGFP-ataxin-3 Q84 fusion protein aggregates in a transiently expressed MJD cell model. HEK 293 cells were transfected with EGFP-ataxin-3 Q28 or EGFP-ataxin-3 Q84 plasmid constructs and their expression was carried out for 24 or 48 hours. (A) Representative schemes of the wild-type (Q28) and expanded (Q84) ataxin-3 fusion protein being expressed. (B) Total extracts prepared from HEK293 cells transfected with EGFP-ataxin-3 (Q28) or (Q84) were analysed through western blotting for ataxin-3 to assess the expression of the plasmid constructs. (C) Representative confocal fluorescent microscopy images of HEK293 cells expressing EGFP-ataxin-3 Q28 (a, b) or EGFP-ataxin-3 Q84 (c, d, e) for 24 (a, c, e) or 48 (b, d) hours. (e) Higher magnification of HEK cells transfected with EGFP-ataxin-3 Q84 for 24 hours. (D) HEK293 cells expressing EGFP-ataxin-3 Q28 or EGFP-ataxin-3 Q84 fusion proteins were fixed, nuclear stained with Hoechst 33342 and quantified through fluorescent microscopy. The graph plots the percentage of cells expressing wild-type (Q28) or expanded (Q84) ataxin-3 fluorescent fusion proteins in three independent transfections.